Clinical trialNCT05224661TerminatedObservational

Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events

SponsorCenter for International Blood and Marrow Transplant ResearchEnrollment303Acute Myeloid Leukemia in Remission

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Christopher Hourigan, DM, D.Phil.
Virginia Polytechnic Institute and State University
Study Chair
clinicaltrials.gov ↗
Jeffrey Auletta, MD
National Marrow Donor Program
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope
Duarte, California, United States
University of California, San Francisco
San Francisco, California, United States
Stanford University
Stanford, California, United States
University of Colorado
Aurora, Colorado, United States
University of Miami
Miami, Florida, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Northside Hospital
Atlanta, Georgia, United States
University of Chicago Medicine
Chicago, Illinois, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
New York Presbyterian / Weill Cornell Medical Center
New York, New York, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
the Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Fred Hutchinson Cancer Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Aug 2022
Primary completion: 12 Dec 2025
Completion: 12 Dec 2025
Last update posted: 1 Jun 2026
Registered enrollment: 303
Registry id: NCT05224661

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.